RE: Steady rise daily17 Apr 2026 08:24
Doesn't make much sense to raise now, the cost controls over the last few years were good, revenues improving, underlying products are rock solid.
Doesn't mean they won't.
The story last time was a bit different - they had a run of really bad luck & really poor mgt decisions, the sp got hammered by the main II exiting, Russia-Ukraine war and massive exodus of investors from health sector after covid. The sp was further being hammered by expectations that a cash raise would be required soon-ish, as they had, from memory, about £1.2m in the bank - still a fair amount, and, considering cash from revenues, they could have just scaled back R&D (rightly or wrongly) for a while instead of diluting.
They issued a strong RNS, claiming that they don't see the need to spend cash any time soon and don't foresee any cash issues, and as sp rallied, they screwed the shareholders with a massive dilution at rock-bottom price.
Whether raising cash at that point in time was the right decision is for us to guess, 'cause we don't have the full picture of the financials & operations at the time, but the way they've done it was borderline criminal.
And several years down the line we are still trading in 15p territory, so up to now the dilution looks like yet another feck up by the mgt.
Still holding as I hope some big pharma will just buy the IP and take the mgt team out of their misery.